

**Calls for proposals for indirect RTD actions under the specific programme for research, technological development and demonstration: “Integrating and strengthening the European Research Area”**

1. In accordance with Decision No 1513/2002/EC of the European Parliament and of the Council, of 27 June 2002, concerning the sixth framework programme of the European Community for research, technological development and demonstration activities contributing to the creation of the European Research Area and to innovation (2002 to 2006)<sup>1</sup>, the Council adopted on 30 September 2002 the specific programme for research, technological development and demonstration: “Integrating and strengthening the European Research Area” (2002-2006)<sup>2</sup> (referred to as “the specific programme”).

In accordance with Article 5(1) of the specific programme, the Commission of the European Communities (referred to as “the Commission”) has adopted on 9 December 2002 a work programme<sup>3</sup> (referred to as “the work programme”) setting out in greater detail the objectives and scientific and technological priorities of the specific programme, and the timetable for implementation.

In accordance with Article 9(1) of the Regulation of the European Parliament and of the Council, of 5 November 2002, concerning the rules for the participation of undertakings, research centres and universities in, and for the dissemination of research results for, the implementation of the European Community Sixth Framework Programme (2002 to 2006)<sup>4</sup> (referred to as “the rules for participation”), proposals for indirect RTD actions should be submitted under the terms of calls for proposals.

2. The present calls for proposals for indirect RTD actions comprise the present general part and the specific conditions that are described in the annexes. These annexes indicate in particular, for each call, the date(s) of closure for the submission of proposals for indirect RTD actions, an indicative date for the completion of the evaluations, the indicative budget, the instruments and the areas concerned, the evaluation criteria for the evaluation of proposals for indirect RTD actions, the minimum number of participants, and any applicable restrictions.
3. Natural or legal persons fulfilling the conditions stated in the rules for participation and that do not fall under any of the exclusion cases in the rules for participation or in Article 114(2) of the Council Regulation (EC, Euratom) No 1605/2002 of 25 June 2002 on the Financial Regulation applicable to the general budget of the European Communities<sup>5</sup> (referred to as “the proposers”) are invited to submit to the Commission proposals for indirect RTD actions subject to the conditions in the rules for participation and in the call concerned being fulfilled.

---

<sup>1</sup> OJ L 232, 29.8.2002, p. 1.

<sup>2</sup> OJ L 294, 29.10.2002, p. 1.

<sup>3</sup> Commission Decision C(2002)4789, unpublished.

<sup>4</sup> To be published.

<sup>5</sup> OJ L248, of 16.9.2002, p. 1.

The European Community has adopted an equal opportunities policy and, on this basis, women are particularly encouraged to either submit proposals for indirect RTD actions or participate in the submission of proposals for indirect RTD actions.

4. The Commission makes available to proposers guides for proposers relating to the calls which contain information on the preparation and the submission of a proposal for an indirect RTD action. These guides, as well as the work programme and other information relating to the calls, can be obtained from the Commission via one of the following addresses:

For the specific programme, with the exception of the priority thematic area of research “Information Society technologies” :

*European Commission  
The FP6 Information Desk  
Directorate General RTD  
B-1049 Brussels, Belgium*

*Email address: [fp6@cec.eu.int](mailto:fp6@cec.eu.int)*

*Internet address: [www.cordis.lu/fp6](http://www.cordis.lu/fp6)*

For the priority thematic area of research “Information Society technologies”:

*European Commission  
The IST Information Desk  
Directorate General INFSO  
B-1049 Brussels, Belgium*

*Email address: [ist@cec.eu.int](mailto:ist@cec.eu.int)*

*Internet address: [www.cordis.lu/ist](http://www.cordis.lu/ist)*

5. Proposals for indirect RTD actions are submitted preferably in electronic format, either on CD-ROM or on diskette. In any case, proposals for indirect RTD actions may also be prepared and submitted using the forms in the guide for proposers (referred to as on “paper”).

Once the software tool within the electronic proposal submission system (EPSS) is available before the closure date in the relevant call, proposals for indirect RTD actions may be prepared off-line or on-line and submitted on-line<sup>6</sup>. The EPSS software tool will be available via the Cordis website [www.cordis.lu](http://www.cordis.lu).

---

<sup>6</sup> For information, the software tool for off-line preparation of proposals for indirect RTD actions should be available at the earliest in January 2003. The tool for on-line preparation and submission of proposals for indirect RTD actions should be available at the earliest end-February 2003.

6. Proposals for indirect RTD actions submitted on CD-ROM, diskette, or paper by post must be received by the Commission at the following address, and labelled as follows:

“FP6 - Research Proposals”  
(Call identifier: ...)  
European Commission  
B-1049 Brussels

For deliveries by hand or by representatives (including by private courier), the delivery should be to the following address, and labelled as follows:

“FP6 - Research Proposals”  
(Call identifier: ...)  
European Commission  
Rue de Genève, 1  
B-1140 Brussels

In both cases, proposals for indirect actions submitted on CD-ROM or on diskette must be accompanied, in the same envelope, by an identical paper version.

Proposals for indirect RTD actions submitted either on CD-ROM or on diskette which are incomplete<sup>7</sup>, illegible<sup>8</sup> or contain viruses will be excluded if a complete corresponding paper version has not been supplied.

Proposals for indirect RTD actions may be submitted on-line<sup>9</sup> via the Cordis website [www.cordis.lu](http://www.cordis.lu).

Proposals for indirect RTD actions that are submitted on-line and which are incomplete<sup>10</sup>, illegible<sup>11</sup> or contain viruses will be excluded.

Proposals for indirect RTD actions that are submitted on paper and which are incomplete<sup>12</sup> will be excluded.

Proposals for indirect RTD actions submitted by email<sup>13</sup> or by fax will be excluded.

7. Proposals for indirect RTD actions have to reach the Commission at the latest on the closure date and at the time specified in the call concerned. Proposals for indirect RTD actions arriving after this date and time will be excluded.

---

<sup>7</sup> All proposals for indirect RTD actions must contain two parts: the forms (Part A) and the content (Part B).

<sup>8</sup> Proposals for indirect RTD actions should be submitted in PDF (“portable document format”, version 3 or higher with embedded fonts) or RTF (“rich text format”).

<sup>9</sup> See footnote 6.

<sup>10</sup> See footnote 7.

<sup>11</sup> See footnote 8.

<sup>12</sup> See footnote 7.

<sup>13</sup> This does not include proposals for indirect RTD actions that have been submitted on-line.

If foreseen in the relevant call, they will be taken up in the framework of a future evaluation.

8. In the case of successive submissions of a proposal in the same format, the Commission will examine the last version received before the closure date and time specified in the call concerned.

In the case where the same proposal for an indirect RTD action is submitted on paper and electronic format (CD-ROM, diskette, on-line), the Commission will only examine the text submitted under the electronic formats.

9. In all correspondence relating to the concerned call (eg, when requesting information, or submitting a proposal for an indirect RTD action), proposers are invited to cite the relevant call identifier.

## ANNEX 1

1. **Specific Programme:** Integrating and strengthening the European Research Area
2. **Activity:** Priority thematic area of research “Life sciences, genomics and biotechnology for health”.
3. **Call title:** Thematic call in the area of “Life sciences, genomics and biotechnology for health”.
4. **Call identifier:** FP6-2002-LIFESCIHEALTH
5. **Date of publication:** 17 December 2002
6. **Closure date(s):** 25 March 2003 at 17.00 (Brussels local time).
7. **Total indicative budget: 513 million €, broken down as follows:**

Instrument <sup>14</sup>	€ (millions)
IP or NOE	385 – 410
STREP or CA	92 – 121
SSA	8 – 10

### 8. Areas called and Instruments:

Proposals are invited in the following topics, which are described using short titles only. For the full titles and definition of topics, applicants must refer to the Work Programme (Section 1.3 Technical Content). The evaluation of proposals will be based on the full definition of topics as described in the Work Programme.

TopicRef.	Short Titles of Topics	Instrument
	<ul style="list-style-type: none"><li>• <i>Gene expression and proteomics</i></li></ul>	
LSH-2002-1.1.1-1	Development of advanced array technologies.	IP or NOE
LSH-2002-1.1.1-2	Development and application of high throughput proteomics technologies for the generation of a large data set of protein-protein interactions.	IP or NOE
	<ul style="list-style-type: none"><li>• <i>Structural genomics</i></li></ul>	
LSH-2002-1.1.2-1	The 3D-structure determination of membrane proteins.	IP or NOE
LSH-2002-1.1.2-2	Supramolecular analysis by 3D-electron microscopy in situ.	NOE

<sup>14</sup> IP = Integrated project; NOE = Network of excellence; STREP = Specific targeted research project; CA = Coordination action; SSA = Specific support action

LSH-2002-1.1.2-3	Development of new hardware and software for the implementation of innovative automated technologies at synchrotron sites.	IP
	• <b><i>Comparative genomics and population genetics</i></b>	
LSH-2002-1.1.3-1	Integrated tools for functional genomics of non-mammalian vertebrate models for human development and disease mechanisms.	IP
LSH-2002-1.1.3-2	Development of <i>in-vivo</i> imaging technologies for phenotyping and functional analysis in cells and animal models.	IP or NOE
	• <b><i>Bioinformatics</i></b>	
LSH-2002-1.1.4-1	Developing methods and resources in bioinformatics to focus the annotation of human and other genomes.	NOE
	• <b><i>Multidisciplinary functional genomics approaches to basic biological processes</i></b>	
LSH-2002-1.1.5-1	Integrated comparative and functional genomics approaches studying the cell cycle.	IP or NOE
LSH-2002-1.1.5-2	Functional genomics of non-human embryonic stem cell differentiation.	IP or NOE
LSH-2002-1.1.5-3	Functional genomics of erythroid development and disorders	IP
LSH-2002-1.1.5-4	Multidisciplinary approaches of functional genomics to study lymphangiogenesis	IP or NOE
LSH-2002-1.1.5-5	Epigenetics: chromatin dynamics, non-coding RNA, imprinting and silencing.	NOE
LSH-2002-1.1.5-6	Multidisciplinary approaches of functional genomics to study chronic Inflammation processes in human disease	NOE
LSH-2002-1.1.5-7	Functional genomics approaches to decipher ubiquitin-proteasome and/or related pathways	NOE
	• <b><i>Across the area</i></b>	
LSH-2002-1.1.0-1	Research should focus on multidisciplinary functional genomics approaches (gene expression and proteomics, structural genomics, comparative genomics, population genetics and bioinformatics) in all organisms to decipher the basic mechanisms underlying the following processes: transcription activation, signal transduction, intracellular communication, the role of non coding genomic information, mechanisms of integration of genes. Proposals dealing with <i>in silico</i> prediction of gene function and for the simulation of complex regulatory networks will also be considered. Proposals concerned with the	STREP/CA

	development of new tools and approaches, including the standardisation of protocols, to facilitate generation of new knowledge in functional genomics are also envisaged. Topics already addressed in the calls for new instruments will not be considered for Specific Targeted Research Project/CA.	
LSH-2002-1.1.0-2	Workshops, conferences, training activities, or publications. The activities supported should be in the context of wider research policy objectives but have a clear link to fundamental genomics. The activities should aim at structuring research activities in fundamental genomics in important areas not yet addressed or newly emerging, including technology foresight meetings to identify future opportunities within the field. Furthermore, they should address opportunities for start-up initiatives or strengthen the international dimension in fundamental genomics research, eg. Standardisation, structuring of international genomics initiatives, integration of activities.	SSA

**b) Application of knowledge and technologies in the field of genomics and biotechnology for health**

<b>Topic Ref.</b>	<b>Short Titles of Topics</b>	<b>Instrument</b>
	<ul style="list-style-type: none"> <li><b><i>Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches</i></b></li> </ul>	
LSH-2002-1.2.1-1	Screening for drug candidates targeting aberrant molecular signalling in protein phosphorylation pathways	IP
LSH-2002-1.2.1-2	Genome-based individualized medicines	NOE
LSH-2002-1.2.1-3	Genome-based therapeutic drugs for psychiatric disorders	IP
LSH-2002-1.2.1-4	Novel antiviral therapeutic molecules targeting virus replication and integration	IP
LSH-2002-1.2.1-5	Generation of blood substitutes for critical blood components, in particular oxygen carriers	STREP
LSH-2002-1.2.1-6	New drugs targeting G-protein coupled receptors through pharmacogenomics	STREP
LSH-2002-1.2.1-7	Educational schemes utilising interdisciplinary approaches for the integration of pre-clinical and clinical research (e.g. training events, workshops)	SSA

	<ul style="list-style-type: none"> <li><b><i>Development of new diagnostics</i></b></li> </ul>	
LSH-2002-1.2.2-1	Non-invasive diagnostics and diagnostic procedures; development of markers for ante- and neo- natal screening	NOE
LSH-2002-1.2.2-2	Development of novel non-invasive and repeatable diagnostics using bioinformatics tools	STREP
LSH-2002-1.2.2-3	New diagnostic tools for prion associated diseases	STREP
	<ul style="list-style-type: none"> <li><b><i>Development of new in vitro tests to replace animal experimentation</i></b></li> </ul>	
LSH-2002-1.2.3-1	Combination and application of <i>in vitro</i> cell and sensor technologies in the field of animal <i>in vivo</i> toxicology	IP
LSH-2002-1.2.3-2	Alternative <i>in vitro</i> tests promoting industrial competitiveness in the product screening and development process stages of pharmaceutically- relevant lead compounds	STREP
LSH-2002-1.2.3-3	Technology foresight meeting on test development, validation and implementation	SSA
LSH-2002-1.2.3-4	Workshop on business opportunities in pharmaceutical toxicology	SSA
LSH-2002-1.2.3-5	Partnership event on the development and manufacture of toxicology test methods for regulatory testing needs	SSA
LSH-2002-1.2.3-6	Forum on the achievements in raising awareness on the use of alternative methods in Candidate Countries	SSA
	<ul style="list-style-type: none"> <li><b><i>Development and testing of new preventive and therapeutic tools, such as somatic gene and cell therapies (in particular stem cell therapies, for example those on neurological and neuromuscular disorders) and immunotherapies</i></b></li> </ul>	
LSH-2002-1.2.4-1	Development and production of cell lines for cell based therapies	IP
LSH-2002-1.2.4-2	Optimised allogeneic stem cell transplantation for haematological and neoplastic diseases	IP
LSH-2002-1.2.4-3	New advances in cell based therapies for the regeneration of connective tissue	IP
LSH-2002-1.2.4-4	Development of a European databank comprising recent advances in genomics, proteomics and cell biology for immunotherapies	STREP

LSH-2002-1.2.4-5	Stem cell products for myocardial repair	STREP
LSH-2002-1.2.4-6	Development of vaccine technologies targeted to dendritic cells	STREP
LSH-2002-1.2.4-7	Workshop on technology transfer and identification of bottlenecks (i.e. IPR, regulatory issues) for SMEs in the area of somatic gene and cell therapies	SSA
	<ul style="list-style-type: none"> <li><b><i>Innovative research in post-genomics, which has high potential for application</i></b></li> </ul>	
LSH-2002-1.2.5-1	Post-genomic approaches for tackling asthma and autoimmune diseases	IP
LSH-2002-1.2.5-2	Plant platforms for immunotherapeutic biomolecule production	IP
LSH-2002-1.2.5-3	Combinatorial biosynthesis as a tool for generating new drug candidates	STREP
LSH-2002-1.2.5-4	Exploiting post genomics to produce optically active therapeutic biomolecules by biocatalysis	STREP
LSH-2002-1.2.5-5	Development of precision technology platforms exploiting advances in post genomics (especially towards involvement of health-related SMEs)	STREP
LSH-2002-1.2.5-6	Workshop for identifying new tools in molecular plant biology for medical applications	SSA

ii) **Combating major diseases**

a) **Application-orientated genomic approaches to medical knowledge and technologies**

Topic Ref/	Short Titles of Topics	Instrument
	<ul style="list-style-type: none"> <li><b><i>Combating, cardiovascular disease, diabetes and rare diseases</i></b></li> </ul>	
LSH-2002-2.1.1-1	Molecular pathogenesis of Coronary Artery Disease (CAD) and diagnostic tools for prevention and treatment	IP or NOE
LSH-2002-2.1.1-2	Novel molecular targets for the treatment of obesity in the context of diabetes.	IP or NOE
LSH-2002-2.1.1-3	The role of pancreatic ion channels in defective insulin secretion in type 2 diabetes	IP

LSH-2002-2.1.1-4	Rare disorders of mitochondria or of nuclear organisation with broader implications for biological processes.	IP or NOE
LSH-2002-2.1.1-5	Genomics of heart muscle development and disease.	NOE
LSH-2002-2.1.1-6	Genomics of vascular disease and atherothrombosis.	NOE
LSH-2002-2.1.1-7	Rare disorders of plasma membrane transporters for amino-acids, lipids and sugars	STREP
LSH-2002-2.1.1-8	Aetiology, pathology and prediction of type 1 diabetes in Europe	CA
LSH-2002-2.1.1-9	Network for early clinical trials in rare diseases	CA
LSH-2002-2.1.1-10	Overcoming the challenges of translational research in cardiovascular disease	SSA
LSH-2002-2.1.1-11	Type II diabetes and obesity	SSA
LSH-2002-2.1.1-12	Coordination of rare disease research in Europe, with various stakeholders from research, SMEs and patient organisations	SSA
	<b>• <i>Combating resistance to antibiotics and other drugs</i></b>	
LSH-2002-2.1.2-1	Management of respiratory tract infections.	NOE
LSH-2002-2.1.2-2	Testing anti-viral drug resistance and understanding resistance development.	IP or NOE
LSH-2002-2.1.2-3	Broadening the knowledge base on the molecular mechanisms behind resistance	STREP/CA
LSH-2002-2.1.2-4	Workshop on the structuring of European research activities to more effectively combat drug resistant hospital infections	SSA
LSH-2002-2.1.2-5	Workshop on strategies to address antimicrobial resistance through the exploitation of microbial genomics	SSA
	<b>• <i>Studying the brain and combating diseases of the nervous system</i></b>	
LSH-2002-2.1.3-1	Genomics and neurobiology of affective disorders	IP or NOE

LSH-2002-2.1.3-2	Eating disorders, from genes to behaviour	IP or NOE
LSH-2002-2.1.3-3	Role and mechanisms of protein aggregation in neurodegenerative diseases	IP
LSH-2002-2.1.3-4	Rare hereditary neurological disorders: ataxias	IP
LSH-2002-2.1.3-5	Molecular and cellular basis of brain development	NOE
LSH-2002-2.1.3-6	Human brain tissue research	NOE
LSH-2002-2.1.3-7	Rare monogenic neurological disorders	STREP/CA
LSH-2002-2.1.3-8	Genetics and neurobiology of pain	STREP/CA
LSH-2002-2.1.3-9	Schizophrenia: from genotype to phenotype	STREP/CA
LSH-2002-2.1.3-10	Specific brain research support actions	SSA
	<b>• <i>Studying human development and the ageing process</i></b>	
LSH-2002-2.1.4-1	Genetic factors of longevity and healthy ageing	IP or NOE
LSH-2002-2.1.4-2	Molecular and cellular processes underlying the development of mesodermal organ system	NOE
LSH-2002-2.1.4-3	Molecular basis of bone homeostasis	STREP

**b) Combating Cancer**

<b>Topic Ref.</b>	<b>Short Titles of Topics</b>	<b>Instrument</b>
LSH-2002-2.2.0-1	Translating basic knowledge of functional oncogenomics into cancer diagnoses and treatment.	IP or NOE
LSH-2002-2.2.0-2	Multidisciplinary research to explore and validate molecular targets for innovative treatment.	IP

LSH-2002-2.2.0-3	Networks for treatment and/or prevention clinical trials aimed at improving clinical practice in the light of new molecular knowledge.	NOE
LSH-2002-2.2.0-4	Innovative research in radiation therapy.	IP or NOE
LSH-2002-2.2.0-5	Molecular imaging for early detection of tumours and monitoring of treatment.	IP or NOE
LSH-2002-2.2.0-6	Networking of quality controlled cancer registries and repositories for molecular epidemiology and quality assessment	NOE
LSH-2002-2.2.0-7	Molecular mechanisms involved in organ-specific metastatic growth processes in breast cancer	STREP/CA
LSH-2002-2.2.0-8	Translational research on promising predictive and prognostic markers	STREP/CA
LSH-2002-2.2.0-9	Molecular mechanisms of cancer-related pain	STREP/CA
LSH-2002-2.2.0-10	Workshop on correlative laboratory studies relevant to therapeutic clinical studies	SSA

**c) Confronting the major communicable diseases linked to poverty**

<b>Topic Ref.</b>	<b>Short Titles of Topics</b>	<b>Instrument</b>
	<ul style="list-style-type: none"> <li><i>Developing new promising candidate vaccines, therapies and microbicides</i></li> </ul>	
LSH-2002-2.3.0-1	Development of an HIV vaccine.	IP or NOE
LSH-2002-2.3.0-2	HIV microbicides.	IP or NOE
LSH-2002-2.3.0-3	Biology and pathology of the malaria parasite.	NOE
LSH-2002-2.3.0-4	Tuberculosis vaccine development.	IP or NOE
LSH-2002-2.3.0-5	Development of mucosal vaccines for poverty-related diseases.	IP or NOE

## SSA across thematic priority 1

Topic Ref.	Short Titles of Topics
LSH-2002-0.0.0-1	Promotion of SME participation
	Stimulating international cooperation
	Linking with candidate countries
	Stimulating exploitation
	Realising ERA objectives
	Contributing to the EU strategy for Life Science and Biotechnology
	Supporting policy developments

### 9. Minimum number of participants<sup>15</sup>:

Instrument	Minimum number of participants
IP, NOE, STREP and CA	3 independent legal entities from 3 different MS or AS, with at least 2 MS or ACC.
SSA	1 legal entity from a MS or AS.

### 10. Restriction on participation: None.

### 11. Consortia agreements:

- Participants in IP and NOE are required to conclude a consortium agreement.
- Participants in STREP, CA and SSA resulting from this call are encouraged, but not required, to conclude a consortium agreement.

### 12. Evaluation procedure:

- The evaluation shall follow a single stage procedure;
- Proposals will not be evaluated anonymously;
- The evaluation process may involve “remote” evaluation of proposals;
- Applicants may be invited to discuss their proposal.

### 13. Evaluation criteria: See Annex B of the work programme for the applicable criteria (including their individual weights and thresholds and the overall threshold) per instrument.

### 14. Indicative evaluation and contractual timetable:

- evaluation results: estimated to be available within some 4 months after the closure date
- contract signature: it is estimated that the first contracts related to this call will come into force by the end of 2003.

<sup>15</sup> MS = Member States of the EU; AS (incl. ACC) = Associated States; ACC = Associated candidate countries.  
Any legal entity established in a Member State or Associated State and which is made up of the requested number of participant may be the sole participant in an indirect action.